Free Trial

Motus GI Q1 2023 Earnings Report

Motus GI EPS Results

Actual EPS
-$9.75
Consensus EPS
-$15.90
Beat/Miss
Beat by +$6.15
One Year Ago EPS
N/A

Motus GI Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$440.00 thousand
YoY Revenue Growth
N/A

Motus GI Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Motus GI Earnings Headlines

Don’t buy TSLA stock until you see this
After a surprise all-hands meeting, Elon Musk urged everyone to “hang onto your stock”... Sparking a rebound of around 10% on Tesla (TSLA) stock this past Monday. Leaving many investors pondering whether or not to buy into a position. That is exactly why I am stepping forward this Sunday, March 30th at 1 PM ET.
See More Motus GI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Motus GI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Motus GI and other key companies, straight to your email.

About Motus GI

Motus GI (NASDAQ:MOTS) operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

View Motus GI Profile

More Earnings Resources from MarketBeat